Search
Stifel's Head of Therapeutics Research Paul Matteis shares his take on the sector and discusses names he covers that have key catalyst events
He shares his thoughts on uniQure, Xenon, Alkermes, Compass Pathways, GH Research MindMed, and Dyne. Coverage brought to you by
10 hours ago
From Boston: Stifel Senior Analyst Paul Matteis talks about the orexin class of wakefulness medicines in development, and comments on recent news from companies he covers
He shares his take on biotech and discusses Alkermes, Tekada, Centessa, Jazz, Biogen, Stoke, Alnylam, BridgeBio, Xenon, and more.
Feb 24
Stifel's Paul Matteis joins BiotechTV for Analyst Thursdays from Boston
He provides an in-depth discussion on this week's uniQure data, and upcoming data from Lexeo. Plus, comments on Alnylam, Dyne,...
Jul 11, 2024
Stifel's Paul Matteis covers earnings season and recent clinical data in biotech on Analyst Thursdays
Paul Matteis gives his take on biotech's start to the year and comments on Alnylam, Biogen, Vertex, KalVista, Denali, Acadia, and more.
Feb 22, 2024
Stifel's Paul Matteis joins BiotechTV for Analyst Thursdays
Paul Matteis comments on Biogen and Vertex earnings, discusses recent news on BioMarin and Sage.
Nov 9, 2023
.png){kind=logo}
